Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
Merck
Colorcon
Moodys
Harvard Business School

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,293,756

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,293,756 protect, and when does it expire?

Patent 8,293,756 protects TASIGNA and is included in one NDA.

Protection for TASIGNA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-three patent family members in thirty countries.

Summary for Patent: 8,293,756
Title:Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate
Abstract: A pharmaceutical composition, especially capsules, comprising granules containing nilotinib or a salt thereof with at least one pharmaceutically acceptable excipient. The granules may be produced by a wet granulation process.
Inventor(s): Bruneau; Nathalie (Cran-Gevrier, FR)
Assignee: Novartis AG (Basel, CH)
Application Number:12/442,544
Patent Claim Types:
see list of patent claims
Composition; Formulation; Process; Use;

Drugs Protected by US Patent 8,293,756

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis TASIGNA nilotinib hydrochloride CAPSULE;ORAL 022068-003 Mar 22, 2018 RX Yes No   Start Trial   Start Trial Y   Start Trial
Novartis TASIGNA nilotinib hydrochloride CAPSULE;ORAL 022068-002 Jun 17, 2010 RX Yes No   Start Trial   Start Trial Y   Start Trial
Novartis TASIGNA nilotinib hydrochloride CAPSULE;ORAL 022068-001 Oct 29, 2007 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,293,756

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
06121371Sep 27, 2006
PCT Information
PCT FiledSeptember 25, 2007PCT Application Number:PCT/EP2007/060165
PCT Publication Date:April 03, 2008PCT Publication Number: WO2008/037716

International Family Members for US Patent 8,293,756

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 062980   Start Trial
Australia 2007301977   Start Trial
Brazil PI0719438   Start Trial
Canada 2662571   Start Trial
Chile 2007002766   Start Trial
China 101516344   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Boehringer Ingelheim
Dow
Moodys
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.